Alterity Therapeutics Completes Enrolment in ATH434-201 : vi

– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants...

Related Keywords

Melbourne , Victoria , Australia , New Zealand , California , United States , San Francisco , Hannah Howlett , David Stamler , Remy Bernarda , Nasdaq , European Commission , Alterity Therapeutics , Chief Executive Officer , Multiple System Atrophy , System Atrophy , Multiple System , Media Contacts , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Clinical Trials , Rare Disease ,